SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-18-002282
Filing Date
2018-08-14
Accepted
2018-08-14 09:11:35
Documents
38
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q rxi_10q-063018.htm 10-Q 265539
2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER rxi_10q-ex3101.htm EX-31.1 6753
3 CERTIFICATION rxi_10q-ex3201.htm EX-32.1 3564
  Complete submission text file 0001683168-18-002282.txt   1565188

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE rxii-20180630.xml EX-101.INS 245073
5 XBRL SCHEMA FILE rxii-20180630.xsd EX-101.SCH 16407
6 XBRL CALCULATION FILE rxii-20180630_cal.xml EX-101.CAL 28287
7 XBRL DEFINITION FILE rxii-20180630_def.xml EX-101.DEF 74058
8 XBRL LABEL FILE rxii-20180630_lab.xml EX-101.LAB 145530
9 XBRL PRESENTATION FILE rxii-20180630_pre.xml EX-101.PRE 114394
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 181014584
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1